Manjit S. Bains YOU? Author Swipe

Last 10y

The role of diagnostic laparoscopy in staging distal esophageal adenocarcinoma Open

Stella T. Tsui, Nancy Zhou, Kay See Tan, Junting Zheng, Katherine Gray , et al. · 2025

Should minimally invasive surgery be the standard approach for early-stage thymoma? A 20-year experience Open

Oliver J. Harrison, Kay See Tan, Joseph Dycoco, Katherine D. Gray, Smita Sihag , et al. · 2025

Figure S3 from Clinical Implications of The Cancer Genome Atlas Molecular Classification System in Esophagogastric Cancer Open

Henry Walch, Raktim Borpatragohain, Justin Jee, Walid K. Chatila, Christopher Fong , et al. · 2025

Supplementary Figure S3. Other variables significantly associated with pathologic major response to neoadjuvant therapy, including (A) clinical stage, (B) treatment regimen, (C) tumor grade, and (D) tumor location. (E) Relative contributio…

Figure S2 from Clinical Implications of The Cancer Genome Atlas Molecular Classification System in Esophagogastric Cancer Open

Henry Walch, Raktim Borpatragohain, Justin Jee, Walid K. Chatila, Christopher Fong , et al. · 2025

Supplementary Figure S2. Overall survival comparisons by molecular subtype of the (A) palliative-intent, (B) curative-intent, (C) never-immunotherapy, and (D) ever-immunotherapy cohorts. CIN, chromosomally instable; EBV, Epstein-Barr virus…

Supplementary Methods1 from Clinical Implications of The Cancer Genome Atlas Molecular Classification System in Esophagogastric Cancer Open

Henry Walch, Raktim Borpatragohain, Justin Jee, Walid K. Chatila, Christopher Fong , et al. · 2025

Supplementary Methods

Supplementary Tables1 from Clinical Implications of The Cancer Genome Atlas Molecular Classification System in Esophagogastric Cancer Open

Henry Walch, Raktim Borpatragohain, Justin Jee, Walid K. Chatila, Christopher Fong , et al. · 2025

Supplementary Tables

Figure S1 from Clinical Implications of The Cancer Genome Atlas Molecular Classification System in Esophagogastric Cancer Open

Henry Walch, Raktim Borpatragohain, Justin Jee, Walid K. Chatila, Christopher Fong , et al. · 2025

Supplementary Figure S1. (A) Fraction of genome altered, (B) clinical actionability as defined by OncoKB by molecular subtype, and (C) tumor mutational burden. CIN, chromosomally instable; EBV, Epstein-Barr virus associated; GS, genomicall…

Figure S3 from Clinical Implications of The Cancer Genome Atlas Molecular Classification System in Esophagogastric Cancer Open

Henry Walch, Raktim Borpatragohain, Justin Jee, Walid K. Chatila, Christopher Fong , et al. · 2025

Supplementary Figure S3. Other variables significantly associated with pathologic major response to neoadjuvant therapy, including (A) clinical stage, (B) treatment regimen, (C) tumor grade, and (D) tumor location. (E) Relative contributio…

Figure S1 from Clinical Implications of The Cancer Genome Atlas Molecular Classification System in Esophagogastric Cancer Open

Henry Walch, Raktim Borpatragohain, Justin Jee, Walid K. Chatila, Christopher Fong , et al. · 2025

Supplementary Figure S1. (A) Fraction of genome altered, (B) clinical actionability as defined by OncoKB by molecular subtype, and (C) tumor mutational burden. CIN, chromosomally instable; EBV, Epstein-Barr virus associated; GS, genomicall…

Supplementary Methods1 from Clinical Implications of The Cancer Genome Atlas Molecular Classification System in Esophagogastric Cancer Open

Henry Walch, Raktim Borpatragohain, Justin Jee, Walid K. Chatila, Christopher Fong , et al. · 2025

Supplementary Methods

Supplementary Tables1 from Clinical Implications of The Cancer Genome Atlas Molecular Classification System in Esophagogastric Cancer Open

Henry Walch, Raktim Borpatragohain, Justin Jee, Walid K. Chatila, Christopher Fong , et al. · 2025

Supplementary Tables

Figure S2 from Clinical Implications of The Cancer Genome Atlas Molecular Classification System in Esophagogastric Cancer Open

Henry Walch, Raktim Borpatragohain, Justin Jee, Walid K. Chatila, Christopher Fong , et al. · 2025

Supplementary Figure S2. Overall survival comparisons by molecular subtype of the (A) palliative-intent, (B) curative-intent, (C) never-immunotherapy, and (D) ever-immunotherapy cohorts. CIN, chromosomally instable; EBV, Epstein-Barr virus…

Data from Clinical Implications of The Cancer Genome Atlas Molecular Classification System in Esophagogastric Cancer Open

Henry Walch, Raktim Borpatragohain, Justin Jee, Walid K. Chatila, Christopher Fong , et al. · 2025

Purpose:The Cancer Genome Atlas (TCGA) project defined four distinct molecular subtypes of esophagogastric adenocarcinoma: microsatellite instable (MSI), Epstein–Barr virus (EBV)–associated, genomically stable (GS), and chromosomally insta…

A Novel Frailty Index Can Predict the Short-Term Outcomes of Esophagectomy in Older Patients with Esophageal Cancer Open

Thomas Boerner, Marisa Sewell, Amy L. Tin, Andrew J. Vickers, Caitlin Harrington-Baksh , et al. · 2024

Background: Frailty, rather than age, is associated with postoperative morbidity and mortality. We sought to determine whether preoperative frailty as defined by a novel scoring system could predict the outcomes among older patients underg…

Biologic versus synthetic prosthesis for chest wall reconstruction: a matched analysis Open

Stijn Vanstraelen, Manjit S. Bains, Joseph Dycoco, Prasad S. Adusumilli, Matthew J. Bott , et al. · 2023

OBJECTIVES The aim of this study was to compare postoperative outcomes between biologic and synthetic reconstructions after chest wall resection in a matched cohort. METHODS All patients who underwent reconstruction after full-thickness ch…

Superior sulcus non–small cell lung cancers (Pancoast tumors): Current outcomes after multidisciplinary management Open

Kaitlin McLaughlin, Kay See Tan, Joseph Dycoco, Monica F. Chen, Jamie E. Chaft , et al. · 2023

Prognostic value of circumferential radial margin involvement in esophagectomy for esophageal cancer: a case series Open

Thomas Boerner, Rebecca Carr, Meier Hsu, Kay See Tan, Carlie Sigel , et al. · 2023

Background: Residual tumor at the proximal or distal margin after esophagectomy is associated with worse survival outcomes; however, the significance of the circumferential resection margin (CRM) remains controversial. In this study, we so…

The contribution of microvascular free flaps and pedicled flaps to successful chest wall surgery Open

Stijn Vanstraelen, Barkat Ali, Manjit S. Bains, Farooq Shahzad, Robert J. Allen , et al. · 2023

A Prospective Clinical Trial to Evaluate Mesothelin as a Biomarker for the Clinical Management of Patients With Esophageal Adenocarcinoma Open

Alexander J. Byun, Rachel Grosser, Jennie K. Choe, Nabil P. Rizk, Laura H. Tang , et al. · 2023

Objective: To investigate the utility of serum soluble mesothelin-related peptide (SMRP) and tumor mesothelin expression in the management of esophageal adenocarcinoma (ADC). Background: Clinical management of esophageal ADC is limited by …

Table of contents Open

Lindsay Dankmyer, S. McGrath, G. Alexander Patterson, Eric N. Feins, Edward T. O’Leary , et al. · 2023

Figure S4 from Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer Open

Yelena Y. Janjigian, Francisco Sánchez-Vega, Philip Jonsson, Walid K. Chatila, Jaclyn F. Hechtman , et al. · 2023

CONSORT diagram of sample flow and sequencing success rates.

Tables S1-S5 from Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer Open

Yelena Y. Janjigian, Francisco Sánchez-Vega, Philip Jonsson, Walid K. Chatila, Jaclyn F. Hechtman , et al. · 2023

Supplementary Table 1: Comprehensive clinical data and sample IDs. Supplementary Table 2: Summary of baseline patient and sample characteristics. Supplementary Table 3: List of somatic mutations identified in all samples. Supplementary Tab…

Figure S2 from Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer Open

Yelena Y. Janjigian, Francisco Sánchez-Vega, Philip Jonsson, Walid K. Chatila, Jaclyn F. Hechtman , et al. · 2023

Concordance between copy-number inferred from next generation sequencing and protein overexpression by IHC or gene amplification by FISH.

Data from Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer Open

Yelena Y. Janjigian, Francisco Sánchez-Vega, Philip Jonsson, Walid K. Chatila, Jaclyn F. Hechtman , et al. · 2023

The incidence of esophagogastric cancer is rapidly rising, but only a minority of patients derive durable benefit from current therapies. Chemotherapy as well as anti-HER2 and PD-1 antibodies are standard treatments. To identify predictive…

Supplementary Figure Legends from Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer Open

Yelena Y. Janjigian, Francisco Sánchez-Vega, Philip Jonsson, Walid K. Chatila, Jaclyn F. Hechtman , et al. · 2023

Text legends for Supplementary Figures S1-S4.

Figure S1 from Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer Open

Yelena Y. Janjigian, Francisco Sánchez-Vega, Philip Jonsson, Walid K. Chatila, Jaclyn F. Hechtman , et al. · 2023

Comparison of mutation frequencies in non-MSI-H tumors in the MSK cohort vs. TCGA and comparison of mutation frequencies in primary vs. metastatic samples in the MSK cohort.

Figure S3 from Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer Open

Yelena Y. Janjigian, Francisco Sánchez-Vega, Philip Jonsson, Walid K. Chatila, Jaclyn F. Hechtman , et al. · 2023

Alteration patterns of paired pre- vs post-treatment samples from HER2 positive patients treated with trastuzumab.

Supplementary Figure Legends from Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer Open

Yelena Y. Janjigian, Francisco Sánchez-Vega, Philip Jonsson, Walid K. Chatila, Jaclyn F. Hechtman , et al. · 2023

Text legends for Supplementary Figures S1-S4.

Figure S4 from Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer Open

Yelena Y. Janjigian, Francisco Sánchez-Vega, Philip Jonsson, Walid K. Chatila, Jaclyn F. Hechtman , et al. · 2023

CONSORT diagram of sample flow and sequencing success rates.

Tables S1-S5 from Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer Open

Yelena Y. Janjigian, Francisco Sánchez-Vega, Philip Jonsson, Walid K. Chatila, Jaclyn F. Hechtman , et al. · 2023

Supplementary Table 1: Comprehensive clinical data and sample IDs. Supplementary Table 2: Summary of baseline patient and sample characteristics. Supplementary Table 3: List of somatic mutations identified in all samples. Supplementary Tab…

Fetching topic information...